Skip to contentC
Cardiff Oncology, Inc.
C
CRDFCardiff Oncology, Inc. Q2 2016 · 10-Q
Revenue$104.00K$104.00K+112.2% vs Q2 2015 Net Income-$10.20M-$10.20MN/M vs Q2 2015 EPS Diluted-$0.34-$0.34N/M vs Q2 2015 Operating Income-$9,980,245N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cardiff Oncology, Inc. · CIK 1213037 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$8,396,565N/M Margins · derivedOperating margin-9596.4%+3938.7 pt vs Q2 2015
Net margin-9809.9%+10965.7 pt vs Q2 2015
ended Jun 30, 2016 · filed Aug 4, 2016 · 35 d after period end